company background image
IBP logo

Indo-Bangla Pharmaceuticals DSE:IBP Stock Report

Last Price

৳13.70

Market Cap

৳1.6b

7D

0%

1Y

-19.4%

Updated

24 Jun, 2024

Data

Company Financials

Indo-Bangla Pharmaceuticals Limited

DSE:IBP Stock Report

Market Cap: ৳1.6b

IBP Stock Overview

Manufactures and sells various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally.

IBP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Indo-Bangla Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Indo-Bangla Pharmaceuticals
Historical stock prices
Current Share Price৳13.70
52 Week High৳21.40
52 Week Low৳12.80
Beta0.19
11 Month Change0%
3 Month Change-18.93%
1 Year Change-19.41%
33 Year Change-27.64%
5 Year Change-35.17%
Change since IPO-61.04%

Recent News & Updates

Recent updates

Shareholder Returns

IBPBD PharmaceuticalsBD Market
7D0%5.0%3.9%
1Y-19.4%-20.3%-23.8%

Return vs Industry: IBP matched the BD Pharmaceuticals industry which returned -20.3% over the past year.

Return vs Market: IBP exceeded the BD Market which returned -23.8% over the past year.

Price Volatility

Is IBP's price volatile compared to industry and market?
IBP volatility
IBP Average Weekly Movement6.8%
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement5.4%
10% most volatile stocks in BD Market7.6%
10% least volatile stocks in BD Market3.4%

Stable Share Price: IBP's share price has been volatile over the past 3 months.

Volatility Over Time: IBP's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of BD stocks.

About the Company

FoundedEmployeesCEOWebsite
1954194A. F. M. Huqwww.indo-banglapharma.com

Indo-Bangla Pharmaceuticals Limited manufactures and sells various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. Its principal products include analgesics and antipyretics, anthelmintic, anti-asthmatic, gastroprokinetic and antiemetic, antiprotozoal, non-hormone sex stimulant, non-steroidal, anti-inflammatory, steroids, and vitamins and minerals, as well as respiratory, cardiovascular, central nervous system, dermatology, and gastrointestinal categories. The company markets its products in various forms, such as tablets, capsules, intravenous fluids, liquids, suppositories, and injectables.

Indo-Bangla Pharmaceuticals Limited Fundamentals Summary

How do Indo-Bangla Pharmaceuticals's earnings and revenue compare to its market cap?
IBP fundamental statistics
Market cap৳1.59b
Earnings (TTM)-৳18.08m
Revenue (TTM)৳211.61m

7.5x

P/S Ratio

-88.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IBP income statement (TTM)
Revenue৳211.61m
Cost of Revenue৳182.04m
Gross Profit৳29.58m
Other Expenses৳47.66m
Earnings-৳18.08m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin13.98%
Net Profit Margin-8.55%
Debt/Equity Ratio2.2%

How did IBP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.